biote Corp. returned to profitability in Q3 2023 and is expected to continue to be profitable in the future. The company's growth is driven by the sale of hormone replacement therapy products and ...

We remain focused on accelerating the number of Biote-certified practitioners and further expanding our evidence-based product offerings to promote positive health outcomes for our patients.” ...

biote Corp. (NASDAQ:BTMD) Q4 2024 Earnings Call Transcript March 12, 2025 biote Corp. beats earnings expectations. Reported ...

IRVING, Texas--(BUSINESS WIRE)-- BioTE Holdings, LLC, (Biote), a high-growth, differentiated medical practice-building business within the hormone optimization space ...